ライフサイエンスコーパス: therapeutic strategy

1 on of bacterial function could be a powerful therapeutic strategy.

2 d melanoma cells after surgical removal as a therapeutic strategy.

3 ing this axis might provide an effective PDA therapeutic strategy.

4 inhibition of this axis may represent a new therapeutic strategy.

5 gression, inhibiting CDK4/6 is an attractive therapeutic strategy.

6 ted the utility of autophagy inhibition as a therapeutic strategy.

7 against cancer has emerged as an encouraging therapeutic strategy.

8 thogenic proteins is emerging as a promising therapeutic strategy.

9 ocking IL-6 has been proposed as a promising therapeutic strategy.

10 face receptors and their ligands is a proven therapeutic strategy.

11 immune response could be the most effective therapeutic strategy.

12 umoral GSL expression to identify an optimal therapeutic strategy.

13 of signaling pathways is often the preferred therapeutic strategy.

14 agnosis of RA, and targeting SR-A might be a therapeutic strategy.

15 ns drives discovery of a rationally designed therapeutic strategy.

16 driven development of novel preventative and therapeutic strategies.

17 ameters that control the efficacy of various therapeutic strategies.

18 implications for the development of precise therapeutic strategies.

19 ptoms, but their detection involves specific therapeutic strategies.

20 eye and will inform future prophylactic and therapeutic strategies.

21 way to consider MMP modulators as promising therapeutic strategies.

22 e remains a significant unmet need for novel therapeutic strategies.

23 old age is crucial to develop preventive or therapeutic strategies.

24 d to better patient stratification and novel therapeutic strategies.

25 rucial for the development of diagnostic and therapeutic strategies.

26 e autophagy in SHRF pathogenesis and suggest therapeutic strategies.

27 he pathways underlying HF and may inform new therapeutic strategies.

28 wide, necessitating the development of novel therapeutic strategies.

29 l of AIS and provides tools to realize novel therapeutic strategies.

30 or therapy affects the development of novel therapeutic strategies.

31 new opportunities for the development of new therapeutic strategies.

32 essary to develop expression rescue as novel therapeutic strategies.

33 , limiting the development of diagnostic and therapeutic strategies.

34 mechanisms driving APA in cancer and suggest therapeutic strategies.

35 ces for studying PSCC biology and developing therapeutic strategies.

36 would provide a molecular basis for targeted therapeutic strategies.

37 (+)ER(+) tumors may benefit from alternative therapeutic strategies.

38 tions, making them more tractable to current therapeutic strategies.

39 these proteins for the development of novel therapeutic strategies.

40 tion and for the development of personalised therapeutic strategies.

41 events and require different diagnostic and therapeutic strategies.

42 isease are based upon modern mechanism-based therapeutic strategies.

43 derstanding the virus biology and developing therapeutic strategies.

44 in, a key new insight paving the road to new therapeutic strategies.

45 mpting scientists to develop better targeted therapeutic strategies.

46 one that may be readily combined with other therapeutic strategies.

47 or cells may provide opportunities for novel therapeutic strategies.

48 xisting rescue strategies could reveal novel therapeutic strategies.

49 targeting SEMA7A may open avenues for novel therapeutic strategies.

50 such insights might be translated into human therapeutic strategies.

51 l opportunities in the development of future therapeutic strategies.

52 ently no approved treatments or preventative therapeutic strategies.

53 ment of prevention, mitigation and alternate therapeutic strategies.

54 gnificant unmet clinical need exists for new therapeutic strategies.

55 physiology, development of disease, and new therapeutic strategies.

56 ss of function to develop safe and effective therapeutic strategies.

57 udies suggesting potential targets for novel therapeutics strategies.

58 infection may lead to the development of new therapeutic strategies against chronic CHIKV disease.

59 are promising targets for the development of therapeutic strategies against human immunodeficiency vi

60 ve as the basis for the development of novel therapeutic strategies against typhoid fever.

61 idence that nitazoxanide may be an effective therapeutic strategy against astrovirus disease.

62 dria Ca(2+) transfer may represent a general therapeutic strategy against cancer cells regardless of

63 f immunostimulatory proteins as an effective therapeutic strategy against disseminated tumors.

64 ustrate how PIERCE1 depletion may serve as a therapeutic strategy against KRAS-mutant NSCLC and propo

65 MPK activator may be a potentially effective therapeutic strategy against NSCLC with EGFR(WT).

66 essive astrocytic GABA could be an effective therapeutic strategy against PD.

67 tophagy inhibition and dual ICB therapy as a therapeutic strategy against PDAC.

68 T-cell targeting as a potential postexposure therapeutic strategy against severe Lassa fever, a hypot

69 ported that neurons secrete tau, and several therapeutic strategies aim to prevent the intracellular

70 Thus, there is a significant unmet need for therapeutic strategies aimed at correcting the TGM1 defi

71 Therapeutic strategies aimed at disruption of S100A8/A9

72 n myelination with possible consequences for therapeutic strategies aimed at lowering TMEM106B levels

73 hogenic cell types within cardiac tissue and therapeutic strategies aimed at modifying their activity

74 s disease (AD) is currently untreatable, and therapeutic strategies aimed to slow cognitive decline h

75 An alternative therapeutic strategy aims to rectify the host tissue pat

76 Therapeutic strategies and experimental paradigms should

77 t a source of targets for the development of therapeutic strategies and prognostic biomarkers of HCC.

78 or the prediction of the effects of specific therapeutic strategies and related clinical outcomes.

79 ovide preclinical proof of concept for a new therapeutic strategy and address an unmet need for this

80 o be done, including identifying the optimal therapeutic strategy and predictive biomarkers.

81 of EGFR-mutant gliomas, uncovering potential therapeutic strategies, and provides new tools for funct

82 Promising therapeutic strategies are emerging for all of these dis

83 poorly to first-line treatments and thus new therapeutic strategies are sought.

84 As such, new targets and therapeutic strategies are urgently required.

85 he rationale and clinical outcome of current therapeutic strategies as well as prospective clinical t

86 esent attractive genome-editing toolsets for therapeutic strategies at the genetic level.

87 lication barrier and present PIAA as a valid therapeutic strategy augmenting functional beta-cells.

88 Together, these data strongly suggest that therapeutic strategies based on the disruption of SHH/PT

89 nhibitors (HDAC6is) have arisen as promising therapeutic strategies, but with partial benefits.

90 um-based chemotherapy represents a promising therapeutic strategy by suppressing therapy-induced sene

91 n patients with the advanced stages, several therapeutic strategies can be used including mono and/or

92 against virus (ImmTAV) molecules represent a therapeutic strategy combining an affinity-enhanced T Ce

93 CRS/HIPEC is an effective therapeutic strategy commonly used to treat peritoneal s

94 se processes may lead to the design of novel therapeutic strategies complementary to current angiogen

95 Therapeutic strategies directed towards enhancing Ly6c(L

96 geting mutant interactomes was proposed as a therapeutic strategy, druggable interactors for rescue o

97 ) and found associations directly suggesting therapeutic strategies (e.g., Omega-6 supplementation an

98 While several therapeutic strategies exist for depression, most antide

99 nts to treat advanced diseases and to design therapeutic strategies exploiting vulnerabilities of can

100 ight potentially be exploited to develop new therapeutic strategies for a range of age-related condit

101 um represents a rich resource to develop new therapeutic strategies for acute COVID-19 and potential

102 These studies will aid the design of therapeutic strategies for cancer using residue-specific

103 arget for designing effective preventive and therapeutic strategies for chronic HCV infection and its

104 s and reveal novel prognostic biomarkers and therapeutic strategies for CRC.

105 ven IR may assist development of AT-targeted therapeutic strategies for diabetes.

106 m of action for ACVR1 mutations, and suggest therapeutic strategies for DIPGs.

107 vestigations are essential to identify novel therapeutic strategies for efficacious treatment for NSC

108 Here, we explore combinatorial therapeutic strategies for either preventing or eliminat

109 isease and could be useful for the design of therapeutic strategies for fighting SARS-CoV-2 infection

110 nt stem cell-derived cardiomyocyte and novel therapeutic strategies for heart disease.

111 itizer could be employed to augment existing therapeutic strategies for HRD cancers.

112 microbiota or T cell migration may represent therapeutic strategies for hyperparathyroidism.

113 tailed understanding of which should lead to therapeutic strategies for inhibiting and depleting onco

114 tunities will emerge to identify targets and therapeutic strategies for IPF.

115 logic agents have become a core component of therapeutic strategies for many inflammatory rheumatic d

116 To identify therapeutic strategies for MYCN-overexpressing SCLC, we

117 Current therapeutic strategies for Parkinson's disease (PD) aim

118 mor biomarker tests (TBTs) are used to guide therapeutic strategies for patients with cancer.

119 sion, and immunity to develop preventive and therapeutic strategies for people of all age groups.

120 Finally, we list therapeutic strategies for preventing the degradation of

121 ears, the search toward novel and less-toxic therapeutic strategies for T-ALL/T-LBL patients has larg

122 des opportunities to develop immune-targeted therapeutic strategies for testing in PD, and clinical s

123 Our work may provide novel therapeutic strategies for the metastasis of GC.

124 highlight some of the novel pharmacological therapeutic strategies for the treatment and prevention

125 n inflammatory environment may provide novel therapeutic strategies for the treatment of OA.

126 s CFTR modulators suggest position-dependent therapeutic strategies for these disease-inflicting muta

127 euron-cancer interactions will elucidate new therapeutic strategies for these presently lethal brain

128 To develop therapeutic strategies for this disease subset, we perfo

129 pathology will aid the development of novel therapeutic strategies for this disease.

130 is will aid the development of new, targeted therapeutic strategies for this neurodegenerative disord

131 development of alternate and effective novel therapeutic strategies for TNBC.

132 e efforts in developing novel virus-targeted therapeutic strategies for treating the devastating huma

133 m outlined here offers new venues for future therapeutic strategies for upstream mutations in cancer,

134 ilization is considered a safe and effective therapeutic strategy for accelerating the rehabilitation

135 ider how these cells could be modulated as a therapeutic strategy for AD.

136 enous secreted Klotho represents a promising therapeutic strategy for aging-associated cardiomyopathy

137 iorate synaptic defects could be a potential therapeutic strategy for autism.

138 for tumorigenesis has emerged as a potential therapeutic strategy for cancer.

139 f JAK/STAT signaling and LSD1 is a promising therapeutic strategy for CEBPA/CSF3R mutant AML.

140 py-induced hyperprogression and illustrate a therapeutic strategy for chemoresistant and desmoplastic

141 geting the Wnt pathway may represent a novel therapeutic strategy for cohesin-mutant cancers.

142 acity, KynA reduction has been proposed as a therapeutic strategy for conditions of cognitive deficit

143 dy points to the potential of an alternative therapeutic strategy for diabetes by targeting specific

144 Utrophin modulation is a promising therapeutic strategy for Duchenne muscular dystrophy (DM

145 tinoic acid pathway offers another potential therapeutic strategy for glomerular disease.

146 These studies reveal a promising therapeutic strategy for KRAS-mutant NSCLCs, identify a

147 ostatin signalling is unlikely to be a valid therapeutic strategy for LGMD R1.

148 nhibit eosinophil recruitment may serve as a therapeutic strategy for management of eosinophilic infl

149 V interneurons, EA may represent a promising therapeutic strategy for managing adolescent substance u

150 o supplementation has emerged as a potential therapeutic strategy for managing CKD.

151 R1 or MEK inhibitors may offer an attractive therapeutic strategy for NSCLC.

152 inhibition represents a novel and promising therapeutic strategy for patients with NPM1mut or MLL-r

153 ed to SNCA, is a promising disease-modifying therapeutic strategy for PD and other alpha-synucleinopa

154 ng KDM5A/MPC-1 signaling may be an effective therapeutic strategy for PDA.

155 e HIF isoform-specific inhibition as a novel therapeutic strategy for PH and right heart failure.

156 ctivation of PKM2 is a novel, and promising, therapeutic strategy for photoreceptor neuroprotection.

157 ing and suggest that targeting Cx43 may be a therapeutic strategy for preventing heart dysfunction an

158 deacetylases (HDAC) has been evaluated as a therapeutic strategy for pulmonary hypertension (PH) in

159 t the maternal SNORD116 locus is a potential therapeutic strategy for PWS.

160 vasodilatation and is therefore a potential therapeutic strategy for restoring uteroplacental perfus

161 salvaging PNKP's activity can be a promising therapeutic strategy for SCA3.

162 sm and identify tau reduction as a potential therapeutic strategy for some of the disorders that caus

163 Counteracting high TLX is a potential therapeutic strategy for suppressing tumours originating

164 ng neuroinflammation might represent a novel therapeutic strategy for SVD.

165 f IDOL activity in the brain may represent a therapeutic strategy for the treatment of AD.

166 etylase 6 (HDAC6) has emerged as a promising therapeutic strategy for the treatment of cancer, chemot

167 tion of CB1R and iNOS represents a promising therapeutic strategy for the treatment of dyslipidemia.

168 f meningeal lymphangiogenesis could be a new therapeutic strategy for the treatment of HE.

169 Our study reveals not only a potential therapeutic strategy for the treatment of IBD but also a

170 way in osteoblasts, offering a potential new therapeutic strategy for the treatment of NF1.

171 Inhibition of DUX4 may represent a therapeutic strategy for these diseases.

172 gh myostatin inhibition, represents a viable therapeutic strategy for this disease.

173 ple myeloma in vitro and in vivo, offering a therapeutic strategy for this malignancy.

174 redox regulation and identifies a promising therapeutic strategy for treatment of CRC.

175 eration and angiogenesis and may represent a therapeutic strategy for treatment of ischemic disorders

176 nced delivery to develop a clinically viable therapeutic strategy for tumours overexpressing the epid

177 pho-regulation of RNF43 might be a potential therapeutic strategy for tumours with RNF43 mutations.

178 or similar compounds may constitute a novel therapeutic strategy for VS, a condition for which there

179 future mechanistic studies on diagnostic and therapeutic strategies, for example, cellular therapy tr

180 ronchial asthma, which possibly offers novel therapeutic strategies, for example, with ASM blockade.

181 ferent human cancers, but the development of therapeutic strategies has been challenging.

182 patients with NUP98-rearranged malignancies, therapeutic strategies have been considered that target

183 to minimize this genetic complexity, recent therapeutic strategies have focused on the neuropeptides

184 To optimize patient-specific therapeutic strategies, here we couple pathway knowledge

185 of effective prevention, early detection and therapeutic strategies; however, additional life-course

186 n the control of autoinflammation and inform therapeutic strategies in COPA syndrome.

187 ata may contribute to the development of new therapeutic strategies in prevention of mother-to-child

188 thogenesis of COVID-19 and discuss potential therapeutic strategies in the management of patients wit

189 gut microbiome is a promising preventive and therapeutic strategy in a number of clinical scenarios.

190 cal evidence for using a SHP2 inhibitor as a therapeutic strategy in acquired EGFRi-resistant NSCLC.

191 tase subtilisin/kexin type 9 inhibitors as a therapeutic strategy in adults with sepsis.

192 f Bruton tyrosine kinase (BTK), is a leading therapeutic strategy in B-cell malignancies, including c

193 geting mortalin has potential as a selective therapeutic strategy in B-Raf-mutant or MEK-ERK-driven t

194 ing inhibitors of PGE2 signaling may offer a therapeutic strategy in cancer and neurological disorder

195 Targeting Mcl-1 may be a therapeutic strategy in EAC.

196 itochondrial function holds promise as a new therapeutic strategy in multiple sclerosis.

197 suggest spliceosome targeting as a promising therapeutic strategy in myeloma.

198 s dual MEK and YAP inhibition as a potential therapeutic strategy in RAS-hyperactivated neuroblastoma

199 Simvastatin appears to be a promising therapeutic strategy in this setting.

200 New therapeutic strategies, including modifications of intra

201 the molecular pathogenesis of HD and future therapeutic strategies, including the modulation of DNA

202 clinical trial design, we can envision novel therapeutic strategies informed by defined molecular mec

203 termine whether the efficacy and safety of a therapeutic strategy involving low-dose intracoronary al

204 Clinically, no therapeutic strategy is available that specifically atte

205 ebral artery occlusion stroke model, a novel therapeutic strategy is proposed, where blood replacemen

206 Before designing adequate therapeutic strategies, it is extremely essential to dia

207 use of peptide- and protein-based agents in therapeutic strategies, it is fundamental to develop del

208 or outcomes and submit that immunomodulatory therapeutic strategies may offer a benefit for this mole

209 This therapeutic strategy may alter myocardial energy metabol

210 in preclinical models, our data support the therapeutic strategy of inhibiting Grb14 to treat diabet

211 In this review, the therapeutic strategy of using ultrasound for improved dr

212 However, treatment of cancer by various therapeutic strategies often fail.

213 ssion levels of Notch1 offers an addition to therapeutic strategies recruited for managing cancer.

214 dvanced insights into disease mechanisms and therapeutic strategies require a deeper understanding of

215 nsplantation and NF-kappaB1 pathway-targeted therapeutic strategies should be considered in the futur

216 insulin sensitivity in mice, indicating that therapeutic strategies should weigh more on FAHFA admini

217 inflammation-driven cancer, we also revisit therapeutic strategies targeting inflammation and immuno

218 th disparities will help in developing novel therapeutic strategies targeting mitochondria to reduce

219 ic value of mutant p53 and current status of therapeutic strategies targeting mutant p53.

220 r the response to CSF1R inhibitors and other therapeutic strategies targeting TAMs.

221 anding of G1/S control will lead to improved therapeutic strategies targeting the cell cycle in cance

222 phenotype may facilitate the design of novel therapeutic strategies targeting these 'master' regulato

223 We present a therapeutic strategy termed "targeted chemotherapy" by d

224 modulation of PrLD phosphorylation may offer therapeutic strategies that are specific for solid-phase

225 between LSCs in CML and AML and examine the therapeutic strategies that could be used to eradicate t

226 We review the major therapeutic strategies that have been considered for sep

227 ents at high risk and describes the emerging therapeutic strategies that may break the inexorable lin

228 lly, we highlight some of the most promising therapeutic strategies that may help combat antifungal r

229 This raises the question of whether therapeutic strategies that reduce inflammation may be u

230 Therefore, therapeutic strategies that target KIT independently of

231 Toward novel therapeutic strategies that target or evade these phenom

232 C-1/PC-2 heteromers in ADPKD and suggest new therapeutic strategies that would expand upon the limite

233 We identified a novel therapeutic strategy that activates a vasculoprotective

234 idases CD73 and CD39, represents a promising therapeutic strategy that may synergize with other immun

235 eve that a co-targeting approach is a viable therapeutic strategy that should be developed further in

236 ells, when instructed appropriately, offer a therapeutic strategy that switches the focus from the ca

237 This study suggests an improved therapeutic strategy, through combined treatment with ST

238 e tested this hypothesis using two potential therapeutic strategies to alter the lipoprotein/protein

239 iral immune response and proposing potential therapeutic strategies to correct the dysregulation.

240 as a metastasis-suppressor gene and suggests therapeutic strategies to counteract metastatic dissemin

241 Current efforts are focused on identifying therapeutic strategies to drive deeper molecular respons

242 pecific cancer phenotypes and we propose new therapeutic strategies to effectively target CIC-altered

243 These findings support therapeutic strategies to enhance BMP9 or BMP10 signalin

244 resistance, it is essential to design novel therapeutic strategies to improve the prognosis for brea

245 this mechanism provide a rational basis for therapeutic strategies to inhibit alphavbeta8-mediated L

246 o achieve antibody neutralization and inform therapeutic strategies to inhibit viral infection.

247 drial dysfunction, may aid in the search for therapeutic strategies to manage PD and related neuropat

248 nfection and discuss ongoing and prospective therapeutic strategies to modulate macrophage activation

249 SMPD1 are new potential target molecules for therapeutic strategies to overcome 5-FU resistance.

250 chondrial function have emerged as promising therapeutic strategies to prevent and treat kidney injur

251 ns for the management of CNV and lead to new therapeutic strategies to prevent atrophy progression.

252 inophils might enable the development of new therapeutic strategies to prevent or inhibit allergic an

253 DAMTS13 and anti-NET treatments could be new therapeutic strategies to promote skin allograft longevi

254 In this context, therapeutic strategies to reactivate or silence astrocyt

255 cal model will serve as a tool for screening therapeutic strategies to reduce/eliminate HIV reservoir

256 We also address the clinical implications of therapeutic strategies to remove or alter specific artic

257 in pathologic conditions, several promising therapeutic strategies to restore the damaged glycocalyx

258 will remain important for new diagnostic and therapeutic strategies to slow or reverse liver disease

259 nt status of OXPHOS inhibitors and potential therapeutic strategies to strengthen their clinical appl

260 on from primary tumor cells may be promising therapeutic strategies to suppress metastasis.

261 inflammasome will direct the development of therapeutic strategies to target infectious and inflamma

262 ll lend insights into the development of new therapeutic strategies to target mast cells during anaph

263 ncept is also likely useful in designing new therapeutic strategies to target nucleolar dysfunction.

264 ceptor (RXR) has been proposed as one of the therapeutic strategies to treat individuals with metabol

265 we have the opportunity to evaluate the best therapeutic strategies to treat RAS-driven cancers.

266 e plasminogen activator receptor (uPAR) as a therapeutic strategy to attenuate acute kidney injury in

267 eration, thereby elucidating a potential new therapeutic strategy to combat AMD.

268 e BMP4-SMAD7 signaling axis presents a novel therapeutic strategy to combat metastatic breast cancer,

269 ipose tissue (WAT) has gained attention as a therapeutic strategy to combat obesity.

270 d brain metastasis development, suggesting a therapeutic strategy to combat the disease and demonstra

271 , suggesting AnxA1-based peptides as a novel therapeutic strategy to control pneumococcal pneumonia.

272 argeting of macrophage metabolism as a novel therapeutic strategy to improve heme clearance in patien

273 nhibiting DNA damage repair is proposed as a therapeutic strategy to improve outcomes for patients wi

274 of tumor-derived vesicles may be a promising therapeutic strategy to improve the efficacy of chemothe

275 Our findings may lead to a therapeutic strategy to increase energy expenditure in o

276 , targeting platelet CypD may be a potential therapeutic strategy to limit brain damage following isc

277 an allosteric mechanism provides a potential therapeutic strategy to overcome drug-resistant EGFR mut

278 roperties, and targeting SHP2 may serve as a therapeutic strategy to overcome tumor resistance to osi

279 uch, targeting CK capacity and flux may be a therapeutic strategy to prevent and treat systolic failu

280 blocking LTB(4) actions could be a promising therapeutic strategy to prevent inflammasome-mediated di

281 herefore, targeting Hippo signaling may be a therapeutic strategy to prevent the development and prog

282 logical CatC inhibition could be a potential therapeutic strategy to prevent the irreversible pulmona

283 nclusion, improving autophagic flux may be a therapeutic strategy to protect endothelial function fro

284 indicate that recombinant uPA is a potential therapeutic strategy to protect the synapse before the d

285 resistant BRAF(V600E)-mutant melanoma and a therapeutic strategy to reduce progression toward BRAF i

286 on drives SCLC chemoresistance and provide a therapeutic strategy to restore chemosensitivity.

287 e to immuno-oncologic therapies, providing a therapeutic strategy to restore immune permissiveness in

288 ical targeting of PRL2 could provide a novel therapeutic strategy to restore PTEN, thereby obliterati

289 ts use of a synthetic LXR agonist as a novel therapeutic strategy to stimulate antitumor activity.

290 e findings further support Cu chelation as a therapeutic strategy to target oncogene-dependent tumor

291 n harnessing the innate immune response as a therapeutic strategy to treat AD.

292 ized and in our view clinically translatable therapeutic strategy to treat NS-associated hypertrophic

293 ) current has been identified as a promising therapeutic strategy to treat various heart rhythm disea

294 We discuss current therapeutic strategies utilizing agonists and antagonist

295 To devise potential combination therapeutic strategies, we identified actionable alterat

296 ne whether lowering TMEM106B may be a viable therapeutic strategy, we performed brain transcriptomic

297 Naturally, the efficacy of these therapeutic strategies will depend on inner retinal stru

298 t not native nNOS, and it suggests that this therapeutic strategy will likely be highly selective.

299 BET-KAc binding has emerged as an attractive therapeutic strategy with a number of small molecule inh

300 ysis by targeting Gpi1 could be an effective therapeutic strategy with minimum toxicity for Th17-medi